Zurcher Kantonalbank Zurich Cantonalbank Has $23.11 Million Stock Holdings in IDEXX Laboratories, Inc. $IDXX

Zurcher Kantonalbank Zurich Cantonalbank increased its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 52.4% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 34,156 shares of the company’s stock after purchasing an additional 11,738 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in IDEXX Laboratories were worth $23,108,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in IDXX. Empowered Funds LLC boosted its stake in IDEXX Laboratories by 6.6% during the 1st quarter. Empowered Funds LLC now owns 1,538 shares of the company’s stock valued at $646,000 after purchasing an additional 95 shares during the last quarter. Sivia Capital Partners LLC bought a new stake in IDEXX Laboratories during the 2nd quarter worth approximately $265,000. Jump Financial LLC increased its holdings in IDEXX Laboratories by 1,006.4% during the 2nd quarter. Jump Financial LLC now owns 5,532 shares of the company’s stock worth $2,967,000 after purchasing an additional 5,032 shares in the last quarter. Cary Street Partners Financial LLC bought a new position in shares of IDEXX Laboratories in the second quarter valued at approximately $164,000. Finally, Sei Investments Co. lifted its holdings in shares of IDEXX Laboratories by 218.7% in the second quarter. Sei Investments Co. now owns 120,587 shares of the company’s stock valued at $64,678,000 after purchasing an additional 82,755 shares in the last quarter. 87.84% of the stock is currently owned by institutional investors and hedge funds.

IDEXX Laboratories Trading Down 2.4%

NASDAQ:IDXX opened at $569.01 on Wednesday. The company has a current ratio of 1.23, a quick ratio of 0.90 and a debt-to-equity ratio of 0.23. The stock has a market capitalization of $45.19 billion, a PE ratio of 43.54, a price-to-earnings-growth ratio of 3.54 and a beta of 1.72. The firm’s 50 day moving average is $598.62 and its 200 day moving average is $654.42. IDEXX Laboratories, Inc. has a 12 month low of $409.11 and a 12 month high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Monday, February 2nd. The company reported $3.08 EPS for the quarter, topping analysts’ consensus estimates of $2.93 by $0.15. The company had revenue of $1.09 billion for the quarter, compared to analysts’ expectations of $1.07 billion. IDEXX Laboratories had a net margin of 24.62% and a return on equity of 69.78%. IDEXX Laboratories’s revenue was up 14.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.53 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. Sell-side analysts expect that IDEXX Laboratories, Inc. will post 14.54 earnings per share for the current year.

Insider Buying and Selling at IDEXX Laboratories

In other IDEXX Laboratories news, Director Sophie V. Vandebroek sold 1,464 shares of the business’s stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $628.62, for a total transaction of $920,299.68. Following the sale, the director owned 648 shares of the company’s stock, valued at $407,345.76. The trade was a 69.32% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP George Fennell sold 11,345 shares of the business’s stock in a transaction on Tuesday, February 10th. The shares were sold at an average price of $646.72, for a total transaction of $7,337,038.40. Following the sale, the executive vice president directly owned 9,823 shares in the company, valued at $6,352,730.56. The trade was a 53.60% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 45,957 shares of company stock worth $29,862,109. Company insiders own 0.79% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the company. Barclays cut their target price on IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating on the stock in a research report on Thursday, February 5th. Piper Sandler cut their target price on IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating on the stock in a research report on Monday, February 9th. Weiss Ratings cut IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Thursday, January 29th. UBS Group cut their target price on IDEXX Laboratories from $750.00 to $730.00 and set a “neutral” rating on the stock in a research report on Tuesday, February 3rd. Finally, Stifel Nicolaus cut their target price on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a research report on Tuesday, March 31st. Seven research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, IDEXX Laboratories presently has a consensus rating of “Moderate Buy” and a consensus target price of $760.00.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.